490
Views
42
CrossRef citations to date
0
Altmetric
Rapid Communication

Toxicity and death following recreational use of 2-pyrrolidino valerophenone

, , , , , & show all
Pages 899-903 | Received 10 Jul 2013, Accepted 16 Sep 2013, Published online: 11 Oct 2013
 

Abstract

Background. Consumption of substituted cathinones, frequently called ‘legal highs’ or ‘designer drugs’, is increasing in the European Union. In July 2012, the French Medicine Agency listed the substituted cathinone's chemical family as narcotic and psychotropic substances, to restrict their use and distribution. We present, here, the first documented cases of recreational use of 2-pyrrolidino valerophenone (PVP) associated with death for one patient, with post-mortem toxicological analysis. Case reports. Two men purchased the legal high Energy-3 (NRG-3). It can be sold as laboratory reagent and is available from Internet. The oldest died of sudden cardiac arrest. The other experienced visual hallucinations and psychotic symptoms for 24 h. He also presented bilateral mydriasis, sinus tachycardia and rhabdomyolysis. He reported an occasional intranasal use of NRG-3. Analysis of the powder and blood and urine from both men revealed the presence of PVP. Discussion and conclusion. PVP belongs to the substituted cathinones chemical family. These cases highlight the need for emergency physicians, toxicologists and networks of toxicovigilance to control the use of these substances and their dangers, quickly identify cases of severe poisoning associated with the use of new drugs and to develop detection methods.

Acknowledgements

The authors thank the French medicine Agency (ANSM for “Agence Nationale de Sécurité des Médicaments et des produits de santé”), the French Monitoring Centre for Drugs and Drug Addiction (OFDT for “Observatoire Français des Drogues et Toxicomanies) and the police laboratory of Marseille for their collaborations.

Declaration of interest

The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.